Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004
Business Overview: Gilead is a biopharmaceutical company focused on anti-infectives. Key marketed products include Viread and Emtriva (HIV), Hepsera (Hepatitis B), AmBisome (antifungal), and Vistide (CMV). The company also earns royalties from Tamiflu (marketed by Roche).
Key Financial Metrics
| Metric (in thousands) | Q1 2004 | Q1 2003 |
|---|---|---|
| Total Revenues | $309,127 | $165,105 |
| Net Income (Loss) | $114,428 | $(438,054) |
| Diluted EPS | $0.50 | $(2.21) |
| Operating Cash Flow | $98,206 | $20,942 |
| Cash & Marketable Securities | $837,642 | $634,408 |
| Long-Term Debt | $345,331 | $250,323 |
| Gross Margin (Product) | 87.4% | 86.3% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 87% year-over-year, driven primarily by an 80% increase in Viread sales ($193.1M vs. $107.3M) and a 256% increase in royalty/contract revenue ($32.5M vs. $9.1M).
- Profitability Turnaround: The company reported a net income of $114.4M compared to a net loss of $438.1M in Q1 2003. This reversal is largely due to the absence of a $488.6M purchased in-process research and development (IPR&D) charge recorded in Q1 2003 related to the Triangle acquisition.
- Non-Operating Gains: A one-time gain of $20.6M was recognized in Q1 2004 from the fair value adjustment of a warrant for Eyetech Pharmaceuticals stock following its IPO.
- Expense Increases: R&D expenses rose 30% to $53.7M, and SG&A expenses rose 60% to $76.1M, reflecting expanded sales forces and launch costs for Emtriva and Hepsera.
Guidance, Outlook, and Risks
Management Commentary and Guidance
- Viread: Expected to grow 30-35% in 2004, with full-year sales projected between $725M and $775M.
- AmBisome: Full-year sales expected to be lower than 2003 due to competition, projected in the range of $170M to $190M.
- Expenses: Full-year 2004 R&D expenses are expected to be $200M-$220M; SG&A expenses are expected to be $310M-$330M.
- Product Pipeline: Applications for a fixed-dose combination of Viread and Emtriva were submitted in March 2004. Development of Amdoxovir and Clevudine was discontinued.
Risks and Contingencies
- Product Dependence: Significant reliance on Viread and AmBisome for operating income.
- Regulatory & Safety: Potential for new safety issues (e.g., kidney toxicity warnings for Viread) and regulatory actions affecting marketing.
- Reimbursement & Pricing: Pressure from government payors and third-party insurers in the U.S. and Europe could reduce profitability.
- Foreign Currency: Significant exposure to foreign currency fluctuations, though hedging programs are in place.
Investor Verification Checklist
- Viread Growth Sustainability: Verify if the 80% growth rate in Viread sales is sustainable given the 30-35% full-year guidance.
- AmBisome Competition: Assess the impact of new competitors on AmBisome sales, which are projected to decline in 2004.
- Fixed-Dose Combination Approval: Monitor the regulatory approval timeline for the Viread/Emtriva co-formulation.
- One-Time Items: Exclude the $20.6M Eyetech warrant gain and the prior year's $488.6M IPR&D charge when analyzing core operational trends.
- European Reimbursement: Review payment delays and credit risks associated with government-owned customers in Greece, Spain, Portugal, and Italy.